Head to Head Contrast: Tyme Technologies (NASDAQ:TYME) & Bellerophon Therapeutics (NASDAQ:BLPH)

Share on StockTwits

Tyme Technologies (NASDAQ:TYME) and Bellerophon Therapeutics (NASDAQ:BLPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for Tyme Technologies and Bellerophon Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tyme Technologies 0 0 1 0 3.00
Bellerophon Therapeutics 0 0 2 0 3.00

Tyme Technologies presently has a consensus target price of $10.00, suggesting a potential upside of 861.54%. Bellerophon Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 334.78%. Given Tyme Technologies’ higher probable upside, equities analysts plainly believe Tyme Technologies is more favorable than Bellerophon Therapeutics.

Profitability

This table compares Tyme Technologies and Bellerophon Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Tyme Technologies N/A -193.37% -153.74%
Bellerophon Therapeutics N/A 674.04% 71.94%

Institutional & Insider Ownership

19.8% of Tyme Technologies shares are owned by institutional investors. Comparatively, 54.7% of Bellerophon Therapeutics shares are owned by institutional investors. 27.2% of Tyme Technologies shares are owned by company insiders. Comparatively, 53.1% of Bellerophon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility & Risk

Tyme Technologies has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500. Comparatively, Bellerophon Therapeutics has a beta of -0.04, meaning that its stock price is 104% less volatile than the S&P 500.

Valuation and Earnings

This table compares Tyme Technologies and Bellerophon Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Tyme Technologies N/A N/A -$32.98 million ($0.32) -3.25
Bellerophon Therapeutics N/A N/A $2.81 million ($0.34) -2.03

Tyme Technologies is trading at a lower price-to-earnings ratio than Bellerophon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Bellerophon Therapeutics beats Tyme Technologies on 7 of the 10 factors compared between the two stocks.

Tyme Technologies Company Profile

Tyme Technologies, Inc., a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company engages in two programs including INOpulse and BCM. INOpulse is based on proprietary pulsatile nitric oxide delivery device. BCM is based on placebo-controlled clinical trial designed to support CE mark registration in the European Union. Bellerophon Therapeutics was founded in 2009 and is headquartered in Warren, NJ.

Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Critical Comparison: Energy Transfer LP Unit  versus Southcross Energy Partners
Critical Comparison: Energy Transfer LP Unit versus Southcross Energy Partners
Parsons  & Cerner  Head to Head Contrast
Parsons & Cerner Head to Head Contrast
Contrasting Masimo  and Newcardio
Contrasting Masimo and Newcardio
SolarWinds  and MAM Software Group  Financial Comparison
SolarWinds and MAM Software Group Financial Comparison
Piedmont Lithium  & Its Peers Financial Review
Piedmont Lithium & Its Peers Financial Review
Analyzing Hudson Global  and The Competition
Analyzing Hudson Global and The Competition


© 2006-2019 Ticker Report